Prednisolone

Generic Name: Prednisolone

Brand Names: Millipred Dp 6 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₅

CAS Number: 50-24-8

Unique Ingredient Identifier: 9PHQ9Y1OLM

Background: Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication: Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma
Down Syndrome

Interventions: Drug: Asparaginase Erwinia chrysanthemi
Drug: Cyclophosphamide
Biological: Blinatumomab
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Mercaptopurine Oral Suspension
Drug: Methotrexate
Drug: Pegaspargase
Radiation: Radiation Therapy
Drug: Prednisone
Drug: Prednisolone
Drug: Thioguanine
Drug: Vincristine Sulfate

First Posted Date: 2019-04-16

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6720

Registration Number: NCT03914625

Locations: 🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

and more 225 locations

Effect of Prednisolone Treatment on Uterine Natural Killer Cells

Phase 3

Recruiting

Conditions: Recurrent Miscarriage

Interventions: Drug: Prednisolone

First Posted Date: 2019-04-04

Last Posted Date: 2023-12-01

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 84

Registration Number: NCT03902912

Locations: 🇭🇰
The Chinese University of Hong Kong, Hong Kong, Hong Kong

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

Phase 2

Recruiting

Conditions: Richter Syndrome

Interventions: Drug: Cyclophosphamide
Drug: Acalabrutinib
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone
Drug: Rituximab

First Posted Date: 2019-04-02

Last Posted Date: 2023-01-09

Lead Sponsor: University of Birmingham

Target Recruit Count: 105

Registration Number: NCT03899337

Locations: 🇬🇧
Leicester Royal Infirmary, Leicester, United Kingdom
🇬🇧
University College London Hospital, London, United Kingdom
🇬🇧
University Hospital of Wales, Cardiff, United Kingdom

and more 13 locations

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

Phase 3

Completed

Conditions: Prostatic Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Abiraterone acetate
Drug: Olaparib
Drug: Prednisone
Drug: Enzalutamide
Drug: Prednisolone

First Posted Date: 2019-02-08

Last Posted Date: 2024-02-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 793

Registration Number: NCT03834519

Locations: 🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 0081), Los Angeles, California, United States
🇨🇦
Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, Canada
🇺🇸
Beth Israel Deaconess Medical Ctr. ( Site 0093), Boston, Massachusetts, United States

and more 190 locations

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Phase 1

Active, not recruiting

Conditions: Lymphoblastic Lymphoma
T-cell Lymphoma
T-cell Leukemia
Acute Leukemia
Recurrent Disease
Leukemia, Lymphocytic

Interventions: Drug: Palbociclib
Drug: Cytarabine
Drug: Methotrexate
Drug: Hydrocortisone
Drug: Doxorubicin
Drug: Prednisolone
Drug: Vincristine
Drug: Pegaspargase
Drug: Prednisone

First Posted Date: 2019-01-03

Last Posted Date: 2024-08-16

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 12

Registration Number: NCT03792256

Locations: 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 16 locations

Evaluation of Cortisone Treatment in Children With Acute Facial Nerve Palsy

Phase 4

Recruiting

Conditions: Facial Nerve Diseases
Borrelia Infection of Central Nervous System
Bell Palsy
Facial Palsy

Interventions: Drug: Placebo Oral Tablet
Drug: Prednisolone

First Posted Date: 2018-12-20

Last Posted Date: 2023-10-31

Lead Sponsor: Dalarna County Council, Sweden

Target Recruit Count: 500

Registration Number: NCT03781700

Locations: 🇸🇪
Barn- och ungdomsmedicinska kliniken, Jönköping, Sweden
🇸🇪
HKH Kronprinsessan Viktorias Barn- och ungdomssjukhus, Linköping, Sweden
🇸🇪
Barn- och ungdomskliniken, Vrinnevi sjukhuset, Norrköping, Sweden

and more 12 locations

Spironolactone Versus Prednisolone in DMD

Phase 1

Terminated

Conditions: Muscular Dystrophy, Duchenne

Interventions: Drug: Spironolactone
Drug: Prednisolone

First Posted Date: 2018-12-17

Last Posted Date: 2023-10-23

Lead Sponsor: Kevin Flanigan

Target Recruit Count: 2

Registration Number: NCT03777319

Locations: 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 1 locations

Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum

Not Applicable

Recruiting

Conditions: Erythema Nodosum Leprosum

Interventions: Drug: Placebo
Drug: Methotrexate
Drug: Prednisolone

First Posted Date: 2018-12-14

Last Posted Date: 2023-03-13

Lead Sponsor: London School of Hygiene and Tropical Medicine

Target Recruit Count: 550

Registration Number: NCT03775460

Locations: 🇮🇳
The Leprosy Mission Trust, Delhi, India
🇳🇵
Anandaban Hospital, Kathmandu, Nepal
🇧🇩
TMLI Bangladesh/ DBLM hospital, Dhaka, Bangladesh

and more 4 locations